Grifols SA

GRFS

Company Profile

  • Business description

    Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

  • Contact

    Avinguda de la Generalitat, 152-158
    Parc de Negocis Can Sant Joan
    Sant Cugat del Valles
    Barcelona08174
    ESP

    T: +34 935710500

    E: [email protected]

    https://www.grifols.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - General

    Fiscal Year End

    31 December 2026

    Employees

    23,800

Grifols SA News & Analysis

stocks

6 undervalued stocks with low beta

Berkshire Hathaway and Verizon are among the low-volatility stocks that trade at a discount.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,046.507.000.08%
CAC 408,243.476.040.07%
DAX 4025,127.465.200.02%
Dow JONES (US)49,266.11270.030.55%
FTSE 10010,021.3426.87-0.27%
HKSE26,149.31561.14-2.10%
NASDAQ23,480.0267.16-0.29%
Nikkei 22551,117.261,400.82-2.67%
NZX 50 Index13,717.800.940.01%
S&P 5006,921.460.530.01%
S&P/ASX 2008,720.802.70-0.03%
SSE Composite Index4,082.982.79-0.07%

Market Movers